Evidence map›Paper›PMID 9475354›Full record

ArticleJournal of clinical immunology1998

Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

I Krause, M Blank, Y Shoenfeld

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Intravenous immunoglobulin in lupus panniculitis.Clinical reviews in allergy & immunology · 2010
    Review
  3. Intravenous immunoglobulin for treatment of pemphigus.Clinical reviews in allergy & immunology · 2005
    Review
  4. Article
  5. Intravenous immunoglobulin therapy in antiphospholipid syndrome.Clinical reviews in allergy & immunology · 2005
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

I KrauseDepartment of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
M Blank
Y Shoenfeld
Tel Aviv University · ILSheba Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous immunoglobulins (IVIG) are therapeutic preparations of pooled normal polyspecific immunoglobulin G. We investigated the presence and the in vivo pathogenic potential of autoantibodies against phospholipids and DNA in several commercial IVIG preparations. The presence of autoantibodies and their antiidiotypic antibodies in the IVIG preparations was detected by ELISA. Naive mice were actively immunized with either IVIG preparations or pathogenic monoclonal antibodies (mAbs) against cardiolipin (CL) or DNA, in an attempt to induce autoimmune conditions. The mice were tested for the presence of mouse autoantibodies (auto-Abs) and for clinical parameters of autoimmune diseases. We found high levels of auto-Abs against a panel of phospholipids and DNA, as well as their antiidiotypic Abs, in all the IVIGs. Affinity studies pointed to a lower affinity of auto-Abs of IVIG origin to their respective antigens compared to pathogenic mAbs. Mice immunized with pathogenic anti-CL mAb had high levels of antiphospholipid auto-Abs, accompanied by thrombocytopenia, prolonged aPTT, and an increased fetal resorption rate. Mice immunized with pathogenic anti-DNA mAb had elevated anti-DNA and anti-CL auto-Abs, along with a high erythrocyte sedimentation rate, leukopenia, and significant proteinuria. Following immunization with IgGs from IVIG batches, mice developed high levels of auto-Abs against phospholipids and DNA, similar to mice immunized with pathogenic anti-DNA or anti-CL mAbs, but none of the mice expressed the clinical manifestations compatible with the presence of these autoantibodies. We conclude that commercial IVIG preparations contain high levels of antiphospholipid and anti-DNA auto-Abs, as well as their antiidiotypic Abs. Although these Abs induced the generation of mouse auto-Abs upon active immunization, following idiotypic manipulation they did not prove to be pathogenic in vivo.

Indexed as

AnimalsAntibodies, AnticardiolipinAntibodies, Anti-IdiotypicAntibodies, AntinuclearAntibodies, AntiphospholipidAntibodies, MonoclonalAutoantibodiesDNADNA, Single-StrandedFemaleHumansImmunizationImmunoglobulin Fab FragmentsImmunoglobulin FragmentsImmunoglobulins, IntravenousMiceAntibodies, AnticardiolipinAntibodies, Anti-IdiotypicAntibodies, AntinuclearAntibodies, AntiphospholipidAntibodies, MonoclonalAutoantibodiesDNADNA, Single-StrandedImmunoglobulin Fab FragmentsImmunoglobulin FragmentsImmunoglobulins, Intravenous

Identifiers

PMID9475354
OpenAlexW1595001782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.